|Bid||390.00 x 3000|
|Ask||391.99 x 800|
|Day's Range||388.52 - 403.00|
|52 Week Range||223.25 - 468.55|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||20.28|
|Earnings Date||Jul 20, 2021 - Jul 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||404.97|
Eli Lilly CEO David Ricks called the FDA's approval "surprising," describing the treatment's trial data as "pretty controversial."
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.
It would be no exaggeration to say last week’s FDA decision to approve Aduhelm - Biogen’s (BIIB) treatment for Alzheimer’s - is a landmark result in the fight against the memory-obliterating disease. The therapy is the first targeting the underlying causes of Alzheimer’s to gain the regulators’ consent, although the decision was not without controversy and went against the findings of the advisory panel. Following the approval, Jefferies’ Michael Yee consulted a KOL (key opinion leader) to get a